BLFS logo

BIOLIFE SOLUTIONS INC

BLFSNASDAQ
πŸ† #1947 by market capEarnings Nov 4US Equity
$38.60β–² $1.32 (+3.55%)
Market closed Β· at close
πŸ””
Track BLFS
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 3.5%
7dβ€”
14dβ€”
30dβ–Ό 0.7%
ytdβ–² 59.8%
1yβ–² 43.6%
🏦Market Cap
$1.89B
Small Cap
πŸ“ˆRevenue Growth (YoY)
34.4%
High Growth
πŸ“ŠGross Margin
63.9%
High
πŸ’΅FCF Margin
7.9%
Moderate
βš–οΈP/S Ratio
18.4x
Expensive
Otter Score
76
Strong

Trading Snapshot

Day Range
$37.10 – $38.83
52-Week Range
$17.86 – $39.76
Volume (shares)
301,504
Avg Volume (shares)
β€”
Shares Outstanding
48.9M
Next Earnings
2026-11-04

Fundamentals Snapshot

Annual Revenue
$96M
Last Q Revenue
$28M
P/E Ratio
32.6
P/S Ratio
18.4x
EPS (TTM)
$1.18
Dividend Yield
β€”
Dilution (1yr)
+1.3%
BLFS logo

BIOLIFE SOLUTIONS INC

BLFS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$96Mβ–² +17.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
64.6%β–Ό βˆ’1.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$1Mβ–Ό βˆ’84.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$416Kβ–Ό βˆ’92.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
48.6Mβ–² +1.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$15Mβ–Ό βˆ’$50M YoY
StockOtter Β· stockotter.space

About BIOLIFE SOLUTIONS INC

BioLife Solutions, Inc. (BLFS) operates as a global provider of specialized bioproduction tools and services, primarily catering to the cell and gene therapy industry. Its market reach extends across the United States, Canada, Europe, the Middle East, Africa, and other international regions. The company's offerings are essential for various stages of biologic-based therapy development, spanning from foundational and applied research to large-scale commercial manufacturing. Key products include proprietary biopreservation media, such as HypoThermosol FRS and CryoStor, which are engineered to minimize delayed cell damage and death typically associated with preservation. Complementing these are the ThawSTAR products, an automated line of devices for thawing vials and cryobags, designed to precisely manage the heat and timing for optimal biologic material thawing. BLFS also provides innovative cloud-connected evo shipping containers for the passive storage and secure transport of temperature-sensitive biologics and pharmaceuticals. Additionally, its comprehensive range encompasses liquid nitrogen laboratory freezers, various cryogenic equipment and accessories, and specialized storage services for biological and pharmaceutical products. Products are distributed both directly to customers and through a network of third-party distributors. Established in 1987, BioLife Solutions, Inc. maintains its headquarters in Bothell, Washington.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
76/100

Analyst Ratings

β“˜
Consensus
Buy
15 analysts
Strong Buy2
Buy5
Hold8
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.